$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
What is the correct usage and dosage of lorlatinib/lorlatinib? What should I pay attention to when taking lorlatinib?
2025-10-19 11:44:20
Check Details
Has pralsetinib been included in medical insurance? How much does a box cost
2025-10-19 11:44:20
Check Details
Lung cancer EGFR 20ins becomes the second targeted drug-mobotinib
2025-10-19 11:44:20
Check Details
Patients in Hubei still don’t know where to buy mobotinib? Look here!
2025-10-19 11:44:20
Check Details
Serpatinib is a highly selective and effective oral drug_Corx
2025-10-19 11:44:20
Check Details
How much does a box of Serpatinib cost? Is serpatinib available in China
2025-10-19 11:44:20
Check Details
What should I pay attention to when using entrectinib? How long will it take for entrectinib to become resistant
2025-10-19 11:44:20
Check Details
What is the efficacy of lorlatinib/lorlatinib for advanced non-small cell lung cancer?
2025-10-19 11:44:20
Check Details
What are the contraindications for lorlatinib/lorlatinib? What are the side effects?
2025-10-19 11:44:20
Check Details
Rybrevant Approved in the U.S. to Treat Lung Cancer with EGFR Exon 20 Insertion Mutations
2025-10-19 11:44:20
Check Details
Refractory lung cancer welcomes Rybrevant, the first targeted therapy, with response rate reaching 40%
2025-10-19 11:44:20
Check Details
Canakinumab can reduce lung cancer mortality by 77%?
2025-10-19 11:44:20
Check Details
1
2
...
3978
3979
3980
3981
3982
3983
3984
...
4164
4165
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Elacestrant US Approval and Treatment Planning While Not Yet Available Locally
2
Stiripentol in Dravet Syndrome: Growth, Cognitive Development and Long-Term Follow-Up Management
3
Cabozantinib Overview: Multi-Target TKI Efficacy and Safety Monitoring for Bleeding, Hypertension, Thrombosis
4
Sotorasib (Lumakras): Indications, Dosing, Safety and the Next-Gen KRAS G12C Landscape
5
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
6
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
7
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
8
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
9
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
10
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
11
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
12
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits